Managed Entry Agreements: Overview and Outlook

This presentation provides a detailed overview of Managed Entry Agreements (MEAs) for pharmaceutical products.  It:

  1. Describes what products and countries are suitable for performance-based MEAs
  2. Outlines what makes successful MEAs for pharma companies, payers, and healthcare providers
  3. Discusses the role of MEAs in the future

Authors for this presentation are:

  • Yan Xue, Principal
  • Eleanor Berry, Manager
  • Kathryn Acheson, Associate Consultant
  • Hidden
  • This field is for validation purposes and should be left unchanged.